
Minerva Neurosciences (NERV) Stock Forecast & Price Target
Minerva Neurosciences (NERV) Analyst Ratings
Bulls say
Minerva Neurosciences is positioned to potentially capitalize on a high-demand market with its innovative product candidate, roluperidone. With successful Phase 2a and 3 trials completed, an expected launch in 2029, and a unique mechanism of action compared to current treatments, the drug has the potential for significant sales and a valuation of $1.5B by 2034. The company also has the potential for future capital raises, further supporting the potential success of roluperidone in becoming a game-changing treatment for negative symptoms of schizophrenia.
Bears say
Minerva Neurosciences is currently developing a potential treatment for negative symptoms in schizophrenia, with the company recently initiating a confirmatory Phase 3 trial. However, there is a significant clinical risk that the candidate may fail to meet efficacy endpoints or produce safety/tolerability signals that impair approval and/or commercialization. Additionally, the company's previous Phase 3 trial for this candidate did not meet its primary endpoint, and while there were positive results in its Phase 2b trial, there is still uncertainty around the potential for positive results in the Phase 3 confirmatory trial.
This aggregate rating is based on analysts' research of Minerva Neurosciences and is not a guaranteed prediction by Public.com or investment advice.
Minerva Neurosciences (NERV) Analyst Forecast & Price Prediction
Start investing in Minerva Neurosciences (NERV)
Order type
Buy in
Order amount
Est. shares
0 shares